Aging Signals Converge on the Myxomatous Mitral Valve
Canine myxomatous mitral valve disease offers a useful biological model for understanding how aging reshapes the mitral valve long before overt failure becomes clinically obvious. In this review, the central premise is simple but clinically important: aging is not passive wear and tear. It is an active process marked by inflammaging, cellular senescence, and persistent remodeling signals that can alter valve structure through pathways also implicated in human disease.
The mitral valve does not deteriorate in isolation. It sits inside a tissue environment that changes with age, and that environment becomes increasingly permissive for extracellular matrix disturbance, inflammatory activation, and maladaptive repair. In both dogs and humans, altered valve leaflets are described as inflammatory microenvironments, and that chronic immune signaling helps explain why myxomatous degeneration progresses instead of stabilizing.
One sentence captures the clinical logic: aging cells can keep secreting the very signals that drive their surrounding tissue toward dysfunction.
Senescence, Inflammaging, and the Valve Microenvironment
The review places inflammaging at the center of the disease process. This term refers to chronic, low-grade inflammation that accumulates with age and contributes to disorders across organ systems, including cardiovascular pathology. In that setting, senescent cells become especially relevant. Once cells enter irreversible growth arrest, they do not simply disappear; they can persist in tissues and release a broad array of inflammatory mediators through the senescence-associated secretory phenotype.
In the mitral valve, that secretory activity has direct implications for tissue structure. Persistent inflammatory signaling can encourage extracellular matrix, or ECM, remodeling, disturb cellular behavior, and amplify local damage. The review argues that these forces are particularly relevant to the development of mitral valve myxomatous degeneration, where leaflet architecture gradually changes under the pressure of chronic biological stress.
The canine model matters because dogs naturally develop MMVD in a way that resembles the human form of the disorder. That makes the species a valuable platform for studying the earliest triggers of ECM remodeling rather than only the end-stage anatomy seen after years of disease. The pathobiology is therefore not just descriptive; it is mechanistic. It asks what shifts a normally quiescent valve toward active degeneration.
Quiescent Valve Cells to Myofibroblast-Like Cells
A major focus of the review is the transition from resting valvular interstitial cells, or qVICs, to activated myofibroblast-like VICs, or aVICs. This shift is central to valve remodeling. Quiescent cells help maintain tissue equilibrium, while activated cells adopt a more repair-oriented, contractile phenotype that can also drive fibrosis-like structural change when the signal persists.
Under stress, cells may enter cycle arrest and become senescent, but the process does not stop there. In the valve leaflet, aVICs are described as responding to TGF-β signaling and the mTOR complex in ways that enhance ECM alteration and contribute to systemic inflammation. In practical terms, the valve becomes a site where stress-response biology turns self-perpetuating. Repair machinery becomes remodeling machinery.
This is a plausible mechanism for progressive myxomatous change. TGF-β is widely recognized as a pro-remodeling pathway in many tissues, and mTOR is closely tied to cell growth, metabolism, and senescence-related signaling. When these pathways are activated in the wrong context, they can support the persistence of an abnormal cellular phenotype that keeps rebuilding the matrix in a distorted form.
TGF-β and mTOR as Remodeling Drivers
The review does not present these pathways as isolated molecular curiosities. It places them in a chain of events that links aging to valve degeneration. TGF-β signaling is positioned as a key driver of VIC activation, while mTOR is framed as a regulator that helps sustain the senescence-associated phenotype and the inflammatory milieu around it. Together, these pathways may promote the ECM changes that define myxomatous degeneration.
That interaction is biologically coherent. TGF-β can push cells toward matrix production and phenotypic transformation, while mTOR can influence how cells sense nutrient status, respond to stress, and maintain inflammatory output. In an aging tissue, where the balance between repair and injury is already strained, those signals can tilt the valve toward progressive thickening, loosening, and dysfunction.
The review also places emphasis on the wider immune context. Senescent cells do not act alone; they contribute to immunosenescence, the age-related decline and distortion of immune function. In the valve, that means inflammation is not merely a bystander effect. It becomes part of the structural disease process itself.
Why the Dog Model Matters for Human Valve Disease
Using the domestic dog as a model is not an abstract comparative exercise. It is a way to study an age-related cardiac disorder in a species that develops a naturally occurring form of the disease. That gives researchers an opportunity to examine the biology of aging, immune activation, and ECM change in a setting that resembles the human condition more closely than many induced animal models do.
The canine model is especially relevant because MMVD is common in older dogs and is characterized by the same broad themes seen in human mitral valve degeneration: leaflet remodeling, chronic inflammatory activity, and progressive structural distortion. A model like this allows investigators to ask whether the earliest events are driven by cellular senescence, inflammatory mediators, or signaling pathways such as TGF-β and mTOR before the disease becomes anatomically advanced.
For clinicians, the value lies in mechanism rather than immediate bedside action. The review does not point to a new therapy or a validated biomarker. Instead, it clarifies the biological architecture of disease and strengthens the case for studying aging-related signaling as a targetable process. If senescence and inflammatory remodeling are central to MMVD, then interventions aimed at those pathways may eventually matter more than treating structural damage after it is established.
A Framework for Future Mechanistic Research
This review argues for a fresh view of MMVD as an aging-linked inflammatory and remodeling disorder, not simply a passive degeneration of the mitral valve. The framework is built on three linked elements: inflammaging, senescence, and pathway-driven ECM remodeling. Each helps explain how a valve that begins as quiescent tissue can gradually become a site of persistent structural injury.
The unanswered issue is not whether the valve changes with age; it clearly does. The harder question is how much of that change is driven by reversible signaling events versus permanent tissue remodeling. That distinction will shape future research on prevention and intervention in both veterinary and human cardiology.
For now, the most concrete conclusion is mechanistic: TGF-β, mTOR, and inflammatory mediators appear intertwined in the aging biology of canine MMVD, and the domestic dog remains a strong model for studying the earliest steps in mitral valve degeneration.